ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism.

Yikai Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.